In addition to weight loss benefits, GLP-1 therapy is an effective treatment for type 2 diabetes
so, oopsey, it was pulled from the market
GLP-1/Amylin Combinations Segment is Growing at the Highest Rate in the GLP-1 Receptor Agonist Cardiovascular Therapy Market In 2025, the GLP-1/Amylin Combinations category dominated the GLP-1 Receptor Agonist Cardiovascular Therapy market because of its capacity to offer improved cardiometabolic advantages via supplementary pathways
Clinical studies demonstrate that certain GLP-1 receptor agonists significantly lower the risk of cardiovascular events like heart attacks and strokes in patients with diabetes
Which dose you choose will likely depend upon the clinical situation
Given the complexity of eating disorders, multidisciplinary care is ideal, involving collaboration between primary care providers, psychiatrists or psychologists specializing in eating disorders, and registered dietitians